Welcome to the CURE blog.

/Blog/

Alexion announces major changes, Boston move

Alexion has announced a comprehensive restructuring. Among other changes, the company plans to relocate its headquarters to Boston, MA by mid-2018. The company plans to have approximately 400 positions in Boston. New Haven will be the Company’s Center of Excellence for its world-class complement research and process development teams. Approximately 450 positions will be based in New Haven, including employees working in the research and process development laboratories, the clinical supply and quality teams, nurse case management, and a number of important enterprise business services. Alexion press release article in The Hartford Courant

By |September 12th, 2017|News|0 Comments

Achillion strengthens management team

Achillion Pharmaceuticals has announced that Executive Vice President Joseph Truitt has been promoted to Chief Operating Officer, a new position within Achillion. The Company has also announced the appointment of Avner Ingerman, M.D. as Senior Vice President and Head of Ophthalmology, also a newly created position​ ... more Separately, Achillion announced the termination of a worldwide license and collaboration arrangement on hepatitis C with Janssen Pharmaceuticals, one of the companies of Johnson & Johnson.  ... more

By |September 12th, 2017|News|0 Comments

UConn partners with Zeiss on microscopy

The UConn School of Engineering announced the launch of a new UConn-ZEISS Partnership with the opening of a new, state of the art laboratory, the Reverse Engineering, Fabrication, Inspection and Nondestructive Evaluation (REFINE) Lab ... more The electrical activity of the heart can be monitored via voltage-sensitive dyes. Such dyes have been developed and patented by UConn Health researchers, who have now embarked on commercializing their product for industry as well as academic use ... more PREAT Corporation and UConn have entered into a license agreement to commercialize better dental bridges for tooth repair and restoration ... more

By |September 12th, 2017|News|0 Comments

Corporate venture capital increasingly important

Corporate venture capital has long been an important source of capital for early-stage biotechs and shows no signs of diminishing, with more and more biopharma companies stepping up their investment activity. According to a new report, Pfizer, Celgene and Roche are among drugmakers whose strategic venture arms are becoming increasingly visible, picking up the pace and gaining on the longstanding leaders such as Novartis, Johnson & Johnson and GlaxoSmithKline's SR One unit. The largest recipients of this venture capital are oncology companies, the report said, as well as medical device, central nervous system disease and anti-infectives players. more

By |September 12th, 2017|News|0 Comments

Alexion and UConn partner on rare disease research

Alexion Pharmaceuticals and the University of Connecticut have announced the first award made through the recently launched Alexion-UConn Rare Disease Innovation Fund. Stormy Chamberlain, Ph.D., assistant professor of genetics and genome sciences at UConn Health,  received the fund’s first award. Chamberlain will conduct sponsored research related to neuro-genetic disorders. more

By |September 7th, 2017|News|0 Comments

Christine Slocumb of Clarity Quest Marketing joins The Commons Advisory Committee

The Commons is pleased to welcome Christine Slocumb, President and Founder of Clarity Quest Marketing to The Commons Advisory Committee. Her agency specializes in healthcare, biotech and technology marketing and has locations in Mystic, Connecticut, Ann Arbor, Michigan, and Seattle, Washington. Christine has over 20 years of marketing, business development, and product management experience in Fortune 50 and startup firms. As the founder of Clarity Quest Marketing, she has grown revenues for healthcare and technology firms. She believes marketing must be accountable for producing tangible results and positive ROI. She is an innovative problem-solver with strong acuity for marketing financial analysis, revenue [...]

By |September 7th, 2017|News|0 Comments

BI wins approval for chronic inflammatory drug

The FDA has approved Boehringer Ingelheim Pharmaceuticals’ Cyltezo (adalimumab-adbm) for the treatment of multiple chronic inflammatory diseases. Cyltezo is the first biosimilar – that is, a biologic medical product that is almost an identical copy of an original product manufactured by a different company, in this case AbbVie’s Humira – from Boehringer Ingelheim to be approved by the FDA. more

By |September 7th, 2017|News|0 Comments

New Haven biotech Biohaven explodes in value

A newly public Bio-tech holding company Biohaven has chosen a high profile former bank building in the city’s Central Business District for its new headquarters. The moves comes as the company is reporting amazing results in the stock market amid positive announcements in its drug development efforts.​ more

By |September 1st, 2017|News|0 Comments

Don’t cut HIV aid, Yale School researchers say

Proposed reductions in U.S. foreign aid would have a devastating impact on HIV treatment and prevention programs in countries receiving such aid, an international team of investigators reports. In their paper published online in Annals of Internal Medicine, the team led by researchers at Massachusetts General Hospital (MGH) and the Yale School of Public Health describes how a 33 percent cutback in funds earmarked for HIV/AIDS prevention, treatment and research in recent budget proposals would only save $900 per year of life lost in the countries of South Africa and Côte d’Ivoire. “This study is the first to document the [...]

By |September 1st, 2017|News|0 Comments

Farmington’s Diameter Health wins VA contract

Farmington health tech company Diameter Health is sharing in a three-year, $4 million federal award with a Virginia contractor to analyze health data for veterans. The U.S. Department of Veterans Affairs has made the award to the company, which is a subcontractor for Four Points Technology LLC of Chantilly, Va. Also an award recipient, Four Points is a "service disabled veteran owned small business" that provides software technology to the VA, according to its website. Four Points partners with top manufacturers and software companies to provide information technology. more

By |September 1st, 2017|News|0 Comments